According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1% ...
Medtronic (NYSE:MDT) today announced three-year results from the SMART trial comparing its Evolut heart valve to Edwards' ...
BostonSci secures rights to acquire MiRus' SIEGEL TAVR system with $1.5B equity stake and potential buyout, marking its 3rd ...
Edwards Lifesciences remains a high-quality business with a wide economic moat , but the stock is still overvalued. Click ...
The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional ...
Next up, we have Edwards Life Sciences. Welcome, Bernard. Yes. No, thanks. So look, it is -- we feel good about where we are at as a company. And when I step back and reflect the reason why, I think ...
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its ...
MedPage Today on MSN
Women-only trial supports self-expanding TAVR as the way to go
ALL WOMEN reported alongside 3-year data from SMART ...
The Seismiq 4CE IVL catheter [Image courtesy of Boston Scientific] EuroPCR 2026 brought together a range of treatment developers across interventional cardiology in Paris last week. Technologies on ...
MedPage Today on MSN
BATMAN technique promising in transcatheter mitral valve replacement
Leaflet modification technique developed to prevent LVOT obstruction ...
Minnesota Timberwolves superstar guard Anthony Edwards is expected to play in Game 1 of his team's second-round playoff series against the San Antonio Spurs Monday night, according to ESPN. It's a ...
Anthony Edwards will play in Game 1 Monday night between the Minnesota Timberwolves and San Antonio Spurs. Head coach Chris Finch confirmed in his pregame news conference that Edwards is in the lineup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results